Yale University’s RAPT Therapeutics RAPT Stock Holding History

Yale University’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,011	Closed	-$512K	–	19
2021 Q2	$512K	Buy	+2,011	New	+$376K	0.18%	13

Other funds holding RAPT

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

KXA

KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Yale University's RAPT Position: Q3 2021 in Review

Yale University sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 2,011 shares — an estimated $512K sold.

Yale University first reported a position in RAPT in Q2 2021 and held it in 1 quarter. The position peaked at $512K in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

Yale University reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
Yale University sold 2,011 RAPT Therapeutics shares in Q3 2021, an estimated $512K.
Yale University first reported a position in RAPT Therapeutics in Q2 2021 and held it in 1 quarter.
Yale University's RAPT Therapeutics position peaked at $512K in Q2 2021.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on Yale University's 13F filing for Q3 2021, filed 12 Nov 2021.